Caribou Biosciences shuts down after failing to fund late-stage CAR-T lymphoma trial

Caribou Biosciences, a California-based biotechnology company co-founded by Nobel laureate Jennifer Doudna, has announced it is shutting down following an unsuccessful effort to raise the capital required to fund a late-stage clinical trial of its lead asset — an off-the-shelf (allogeneic) CAR-T cell therapy for lymphoma.

Allogeneic CAR-T approaches use donor-derived cells rather than the patient's own, with the aim of enabling a ready-made product that avoids the lengthy manufacturing timelines associated with autologous therapies. Caribou's programme had advanced to mid-stage clinical evaluation, but the company was unable to bridge the significant financial gap to a pivotal study.

The closure is notable in the context of the broader allogeneic CAR-T field, which has faced repeated setbacks across multiple developers. Fundraising conditions for mid-stage clinical-stage biotechs — particularly those without near-term revenue or partnership backing — have remained difficult. Caribou's winding down comes shortly after STAT News reported on the in-vivo CAR-T engineering work from UCSF (covered separately in this edition), illustrating the range of competing approaches to solving the ex-vivo manufacturing bottleneck in cell therapy.

Reporting on the closure came from STAT News; the article is behind a subscription paywall but sufficient detail was available from the lede for accurate summarisation.